Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Hundreds rally in West Bank against Israeli death penalty for Palestinians - 25 Christmas movies to stream for less with this Paramount+ Black Friday deal
- 3Scientists captured female sperm whales on video working together during a birth to protect the calf
- 4Avoid Large Crowds In Bali & Swim At This Peaceful Waterfall With A Gorgeous, Natural Pool
- 5Partner of crime boss Steven Lyons arrested in Dubai
- Role reversal: Ukraine moves training home and exports the lessons abroad
- UK to hold fresh pork, other affected Spanish products at border amid African swine fever outbreak
- A Republican elected governor in California? It's not as far-fetched as it sounds.
- Comet C/2025 K1 (ATLAS) breaks apart in incredible telescope photos
- Cocaine, caffeine, painkillers consumed by sharks in Bahamas, study finds
- Vote in favor of the pasta that makes good dieting pleasant!
- Step into Nature: A Survey of \Handling Trails with Solace\ Climbing Shoes
- IDF begins destroying homes used by Hezbollah as forces move deeper into southern Lebanon
- Figure out How to Explore Land Close to 5G Pinnacles
